| Epidiolex,CBD |
epilepsy
via review |
Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects |
Feb 2019 |
|
More recently, several randomized controlled and open label trials have studied the effects of Epidiolex, a 99% pure oral CBD extract, on patients with refractory epilepsy. This in turn has led to the FDA approval of and more recently, to the Drug Enforcement Administrations placement of Epidiolex into schedule V of the Controlled Substances Act (CSA)
|
| Epidiolex,CBD |
epilepsy
in humans via trial (n=45) |
Open-label use of highly purified CBD (Epidiolex(R)) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. |
Sep 2018 |
|
This open-label drug trial provides class III evidence for the long-term safety and efficacy of CBD administration in patients with treatment-resistant epilepsy (TRE) associated with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
|
| Epidiolex,CBD |
epilepsy
via review |
Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes. |
Jun 2019 |
|
This is the first cannabis-derived medication with approval from the US Food and Drug Administration. This CBD formulation significantly reduces seizures as an adjunct to standard antiepileptic therapies in patients >=2 years old with DS and LGS and is well tolerated.
|